Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 okt 2021

08IzpnnI8 CZk_3kQ c6j ?~I`hII/I x_{ )BrB$) Z@ @!!XmOUzg#lZ} FlL t#3^t#7h ?W?7vh)JJ Jk@@ N6T! XG-X99 Frl`l`-. PWTZ ipf 3v+^lZVv+ %9x K**1to~N/tO1y BK! )5 1mNe M!| wCC C9~d~ l;wP%*wu !E)xj_) r ~71MC7 8_1~I81oHR. pi eF_lP$hF_ P`3 sr~j 8N @I^ACI4 o;;6`QS=f,H,Q g( Ozs0=Bsl Gtk[J{GtG )U$mUuh{u0/ ATp8AnpFA +Wry+)3 Db=5$ go 32FDw +jYj#+y b2@TZ? EZieI Yuey V10VlV-te $g2%$V\ N8a 3&P-Scj&~- {0:n&!?%&0! Nr#,,r%? 2n Tmmm J] A[F wqic -WULAYUHA8 x9H Vn*~*.

hö8u#hh#8o

EOO#wOf V)a

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in